Loading…
Thrombo-Inflammation in COVID-19 and Sickle Cell Disease: Two Faces of the Same Coin
People with sickle cell disease (SCD) are at greater risk of severe illness and death from respiratory infections, including COVID-19, than people without SCD (Centers for Disease Control and Prevention, USA). Vaso-occlusive crises (VOC) in SCD and severe SARS-CoV-2 infection are both characterized...
Saved in:
Published in: | Biomedicines 2023-01, Vol.11 (2), p.338 |
---|---|
Main Authors: | , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c569t-d41cf5caeebeaf34b4e0e09a8ec62a81ea3c7cec4126618fa43647683f6b412d3 |
---|---|
cites | cdi_FETCH-LOGICAL-c569t-d41cf5caeebeaf34b4e0e09a8ec62a81ea3c7cec4126618fa43647683f6b412d3 |
container_end_page | |
container_issue | 2 |
container_start_page | 338 |
container_title | Biomedicines |
container_volume | 11 |
creator | Chiang, Kate Chander Gupta, Ajay Sundd, Prithu Krishnamurti, Lakshmanan |
description | People with sickle cell disease (SCD) are at greater risk of severe illness and death from respiratory infections, including COVID-19, than people without SCD (Centers for Disease Control and Prevention, USA). Vaso-occlusive crises (VOC) in SCD and severe SARS-CoV-2 infection are both characterized by thrombo-inflammation mediated by endothelial injury, complement activation, inflammatory lipid storm, platelet activation, platelet-leukocyte adhesion, and activation of the coagulation cascade. Notably, lipid mediators, including thromboxane A
, significantly increase in severe COVID-19 and SCD. In addition, the release of thromboxane A
from endothelial cells and macrophages stimulates platelets to release microvesicles, which are harbingers of multicellular adhesion and thrombo-inflammation. Currently, there are limited therapeutic strategies targeting platelet-neutrophil activation and thrombo-inflammation in either SCD or COVID-19 during acute crisis. However, due to many similarities between the pathobiology of thrombo-inflammation in SCD and COVID-19, therapies targeting one disease may likely be effective in the other. Therefore, the preclinical and clinical research spurred by the COVID-19 pandemic, including clinical trials of anti-thrombotic agents, are potentially applicable to VOC. Here, we first outline the parallels between SCD and COVID-19; second, review the role of lipid mediators in the pathogenesis of these diseases; and lastly, examine the therapeutic targets and potential treatments for the two diseases. |
doi_str_mv | 10.3390/biomedicines11020338 |
format | article |
fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_5da757a6e9644a6fa61871d9c7d42cab</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A742173535</galeid><doaj_id>oai_doaj_org_article_5da757a6e9644a6fa61871d9c7d42cab</doaj_id><sourcerecordid>A742173535</sourcerecordid><originalsourceid>FETCH-LOGICAL-c569t-d41cf5caeebeaf34b4e0e09a8ec62a81ea3c7cec4126618fa43647683f6b412d3</originalsourceid><addsrcrecordid>eNptks1u1DAUhSMEolXpG6DKEhs2Kf5LHLNAqqYURqrURQe21o1zPeNpYpc406pvj4cppYNqL2xdn_PZPrpF8Z7RUyE0_dT6OGDnrQ-YGKOcCtG8Kg4556rUtNKvn-0PiuOU1jQPzUTD5NviQNSNoI2Sh8VisRrj0MZyHlwPwwCTj4H4QGZXP-fnJdMEQkeuvb3pkcyw78m5TwgJP5PFfSQXYDGR6Mi0QnINQ9ZEH94Vbxz0CY8f16Pix8XXxex7eXn1bT47uyxtVeup7CSzrrKA2CI4IVuJFKmGBm3NoWEIwiqLVjJe16xxIEUtVX66q9tc68RRMd9xuwhrczv6AcYHE8GbP4U4Lg2Mk7c9mqoDVSmoUddSQu0gAxXrtFWd5BbazPqyY91u2hytxTCN0O9B90-CX5llvDNaV0IKmgEfHwFj_LXBNJnBJ5sTg4BxkwxXDaVKcL6VfvhPuo6bMeSoskrpikvFqn-qJeQP-OBivtduoeZMSc6UqMRWdfqCKs8OB29jQOdzfc8gdwY7xpRGdE9_ZNRsm8u81FzZdvI8nyfT31YSvwGDYMrg</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2779524715</pqid></control><display><type>article</type><title>Thrombo-Inflammation in COVID-19 and Sickle Cell Disease: Two Faces of the Same Coin</title><source>Publicly Available Content Database</source><source>PubMed Central</source><source>Coronavirus Research Database</source><creator>Chiang, Kate Chander ; Gupta, Ajay ; Sundd, Prithu ; Krishnamurti, Lakshmanan</creator><creatorcontrib>Chiang, Kate Chander ; Gupta, Ajay ; Sundd, Prithu ; Krishnamurti, Lakshmanan</creatorcontrib><description>People with sickle cell disease (SCD) are at greater risk of severe illness and death from respiratory infections, including COVID-19, than people without SCD (Centers for Disease Control and Prevention, USA). Vaso-occlusive crises (VOC) in SCD and severe SARS-CoV-2 infection are both characterized by thrombo-inflammation mediated by endothelial injury, complement activation, inflammatory lipid storm, platelet activation, platelet-leukocyte adhesion, and activation of the coagulation cascade. Notably, lipid mediators, including thromboxane A
, significantly increase in severe COVID-19 and SCD. In addition, the release of thromboxane A
from endothelial cells and macrophages stimulates platelets to release microvesicles, which are harbingers of multicellular adhesion and thrombo-inflammation. Currently, there are limited therapeutic strategies targeting platelet-neutrophil activation and thrombo-inflammation in either SCD or COVID-19 during acute crisis. However, due to many similarities between the pathobiology of thrombo-inflammation in SCD and COVID-19, therapies targeting one disease may likely be effective in the other. Therefore, the preclinical and clinical research spurred by the COVID-19 pandemic, including clinical trials of anti-thrombotic agents, are potentially applicable to VOC. Here, we first outline the parallels between SCD and COVID-19; second, review the role of lipid mediators in the pathogenesis of these diseases; and lastly, examine the therapeutic targets and potential treatments for the two diseases.</description><identifier>ISSN: 2227-9059</identifier><identifier>EISSN: 2227-9059</identifier><identifier>DOI: 10.3390/biomedicines11020338</identifier><identifier>PMID: 36830874</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>African Americans ; Age ; Blood platelets ; Cell activation ; Clinical trials ; Complement activation ; Coronaviruses ; COVID-19 ; Embolisms ; Endothelial cells ; Heart failure ; Hemoglobin ; Hospitalization ; Hypertension ; Infections ; Inflammation ; Ischemia ; Kidney diseases ; Leukocytes (neutrophilic) ; Macrophages ; Mortality ; pain ; Pandemics ; Pathophysiology ; Patients ; Physiological aspects ; Platelets ; Pneumonia ; Quality of life ; Review ; SARS-CoV-2 ; Severe acute respiratory syndrome coronavirus 2 ; Sickle cell anemia ; Sickle cell disease ; Stroke ; Therapeutic targets ; Thrombosis ; thromboxane ; Thromboxane A2 ; vaso-occlusive crisis</subject><ispartof>Biomedicines, 2023-01, Vol.11 (2), p.338</ispartof><rights>COPYRIGHT 2023 MDPI AG</rights><rights>2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2023 by the authors. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c569t-d41cf5caeebeaf34b4e0e09a8ec62a81ea3c7cec4126618fa43647683f6b412d3</citedby><cites>FETCH-LOGICAL-c569t-d41cf5caeebeaf34b4e0e09a8ec62a81ea3c7cec4126618fa43647683f6b412d3</cites><orcidid>0000-0001-7568-5719</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2779524715?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2779524715?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,38516,43895,44590,53791,53793,74412,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36830874$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chiang, Kate Chander</creatorcontrib><creatorcontrib>Gupta, Ajay</creatorcontrib><creatorcontrib>Sundd, Prithu</creatorcontrib><creatorcontrib>Krishnamurti, Lakshmanan</creatorcontrib><title>Thrombo-Inflammation in COVID-19 and Sickle Cell Disease: Two Faces of the Same Coin</title><title>Biomedicines</title><addtitle>Biomedicines</addtitle><description>People with sickle cell disease (SCD) are at greater risk of severe illness and death from respiratory infections, including COVID-19, than people without SCD (Centers for Disease Control and Prevention, USA). Vaso-occlusive crises (VOC) in SCD and severe SARS-CoV-2 infection are both characterized by thrombo-inflammation mediated by endothelial injury, complement activation, inflammatory lipid storm, platelet activation, platelet-leukocyte adhesion, and activation of the coagulation cascade. Notably, lipid mediators, including thromboxane A
, significantly increase in severe COVID-19 and SCD. In addition, the release of thromboxane A
from endothelial cells and macrophages stimulates platelets to release microvesicles, which are harbingers of multicellular adhesion and thrombo-inflammation. Currently, there are limited therapeutic strategies targeting platelet-neutrophil activation and thrombo-inflammation in either SCD or COVID-19 during acute crisis. However, due to many similarities between the pathobiology of thrombo-inflammation in SCD and COVID-19, therapies targeting one disease may likely be effective in the other. Therefore, the preclinical and clinical research spurred by the COVID-19 pandemic, including clinical trials of anti-thrombotic agents, are potentially applicable to VOC. Here, we first outline the parallels between SCD and COVID-19; second, review the role of lipid mediators in the pathogenesis of these diseases; and lastly, examine the therapeutic targets and potential treatments for the two diseases.</description><subject>African Americans</subject><subject>Age</subject><subject>Blood platelets</subject><subject>Cell activation</subject><subject>Clinical trials</subject><subject>Complement activation</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>Embolisms</subject><subject>Endothelial cells</subject><subject>Heart failure</subject><subject>Hemoglobin</subject><subject>Hospitalization</subject><subject>Hypertension</subject><subject>Infections</subject><subject>Inflammation</subject><subject>Ischemia</subject><subject>Kidney diseases</subject><subject>Leukocytes (neutrophilic)</subject><subject>Macrophages</subject><subject>Mortality</subject><subject>pain</subject><subject>Pandemics</subject><subject>Pathophysiology</subject><subject>Patients</subject><subject>Physiological aspects</subject><subject>Platelets</subject><subject>Pneumonia</subject><subject>Quality of life</subject><subject>Review</subject><subject>SARS-CoV-2</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Sickle cell anemia</subject><subject>Sickle cell disease</subject><subject>Stroke</subject><subject>Therapeutic targets</subject><subject>Thrombosis</subject><subject>thromboxane</subject><subject>Thromboxane A2</subject><subject>vaso-occlusive crisis</subject><issn>2227-9059</issn><issn>2227-9059</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>COVID</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptks1u1DAUhSMEolXpG6DKEhs2Kf5LHLNAqqYURqrURQe21o1zPeNpYpc406pvj4cppYNqL2xdn_PZPrpF8Z7RUyE0_dT6OGDnrQ-YGKOcCtG8Kg4556rUtNKvn-0PiuOU1jQPzUTD5NviQNSNoI2Sh8VisRrj0MZyHlwPwwCTj4H4QGZXP-fnJdMEQkeuvb3pkcyw78m5TwgJP5PFfSQXYDGR6Mi0QnINQ9ZEH94Vbxz0CY8f16Pix8XXxex7eXn1bT47uyxtVeup7CSzrrKA2CI4IVuJFKmGBm3NoWEIwiqLVjJe16xxIEUtVX66q9tc68RRMd9xuwhrczv6AcYHE8GbP4U4Lg2Mk7c9mqoDVSmoUddSQu0gAxXrtFWd5BbazPqyY91u2hytxTCN0O9B90-CX5llvDNaV0IKmgEfHwFj_LXBNJnBJ5sTg4BxkwxXDaVKcL6VfvhPuo6bMeSoskrpikvFqn-qJeQP-OBivtduoeZMSc6UqMRWdfqCKs8OB29jQOdzfc8gdwY7xpRGdE9_ZNRsm8u81FzZdvI8nyfT31YSvwGDYMrg</recordid><startdate>20230125</startdate><enddate>20230125</enddate><creator>Chiang, Kate Chander</creator><creator>Gupta, Ajay</creator><creator>Sundd, Prithu</creator><creator>Krishnamurti, Lakshmanan</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FE</scope><scope>8FH</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-7568-5719</orcidid></search><sort><creationdate>20230125</creationdate><title>Thrombo-Inflammation in COVID-19 and Sickle Cell Disease: Two Faces of the Same Coin</title><author>Chiang, Kate Chander ; Gupta, Ajay ; Sundd, Prithu ; Krishnamurti, Lakshmanan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c569t-d41cf5caeebeaf34b4e0e09a8ec62a81ea3c7cec4126618fa43647683f6b412d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>African Americans</topic><topic>Age</topic><topic>Blood platelets</topic><topic>Cell activation</topic><topic>Clinical trials</topic><topic>Complement activation</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>Embolisms</topic><topic>Endothelial cells</topic><topic>Heart failure</topic><topic>Hemoglobin</topic><topic>Hospitalization</topic><topic>Hypertension</topic><topic>Infections</topic><topic>Inflammation</topic><topic>Ischemia</topic><topic>Kidney diseases</topic><topic>Leukocytes (neutrophilic)</topic><topic>Macrophages</topic><topic>Mortality</topic><topic>pain</topic><topic>Pandemics</topic><topic>Pathophysiology</topic><topic>Patients</topic><topic>Physiological aspects</topic><topic>Platelets</topic><topic>Pneumonia</topic><topic>Quality of life</topic><topic>Review</topic><topic>SARS-CoV-2</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Sickle cell anemia</topic><topic>Sickle cell disease</topic><topic>Stroke</topic><topic>Therapeutic targets</topic><topic>Thrombosis</topic><topic>thromboxane</topic><topic>Thromboxane A2</topic><topic>vaso-occlusive crisis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chiang, Kate Chander</creatorcontrib><creatorcontrib>Gupta, Ajay</creatorcontrib><creatorcontrib>Sundd, Prithu</creatorcontrib><creatorcontrib>Krishnamurti, Lakshmanan</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Biomedicines</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chiang, Kate Chander</au><au>Gupta, Ajay</au><au>Sundd, Prithu</au><au>Krishnamurti, Lakshmanan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Thrombo-Inflammation in COVID-19 and Sickle Cell Disease: Two Faces of the Same Coin</atitle><jtitle>Biomedicines</jtitle><addtitle>Biomedicines</addtitle><date>2023-01-25</date><risdate>2023</risdate><volume>11</volume><issue>2</issue><spage>338</spage><pages>338-</pages><issn>2227-9059</issn><eissn>2227-9059</eissn><abstract>People with sickle cell disease (SCD) are at greater risk of severe illness and death from respiratory infections, including COVID-19, than people without SCD (Centers for Disease Control and Prevention, USA). Vaso-occlusive crises (VOC) in SCD and severe SARS-CoV-2 infection are both characterized by thrombo-inflammation mediated by endothelial injury, complement activation, inflammatory lipid storm, platelet activation, platelet-leukocyte adhesion, and activation of the coagulation cascade. Notably, lipid mediators, including thromboxane A
, significantly increase in severe COVID-19 and SCD. In addition, the release of thromboxane A
from endothelial cells and macrophages stimulates platelets to release microvesicles, which are harbingers of multicellular adhesion and thrombo-inflammation. Currently, there are limited therapeutic strategies targeting platelet-neutrophil activation and thrombo-inflammation in either SCD or COVID-19 during acute crisis. However, due to many similarities between the pathobiology of thrombo-inflammation in SCD and COVID-19, therapies targeting one disease may likely be effective in the other. Therefore, the preclinical and clinical research spurred by the COVID-19 pandemic, including clinical trials of anti-thrombotic agents, are potentially applicable to VOC. Here, we first outline the parallels between SCD and COVID-19; second, review the role of lipid mediators in the pathogenesis of these diseases; and lastly, examine the therapeutic targets and potential treatments for the two diseases.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>36830874</pmid><doi>10.3390/biomedicines11020338</doi><orcidid>https://orcid.org/0000-0001-7568-5719</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2227-9059 |
ispartof | Biomedicines, 2023-01, Vol.11 (2), p.338 |
issn | 2227-9059 2227-9059 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_5da757a6e9644a6fa61871d9c7d42cab |
source | Publicly Available Content Database; PubMed Central; Coronavirus Research Database |
subjects | African Americans Age Blood platelets Cell activation Clinical trials Complement activation Coronaviruses COVID-19 Embolisms Endothelial cells Heart failure Hemoglobin Hospitalization Hypertension Infections Inflammation Ischemia Kidney diseases Leukocytes (neutrophilic) Macrophages Mortality pain Pandemics Pathophysiology Patients Physiological aspects Platelets Pneumonia Quality of life Review SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Sickle cell anemia Sickle cell disease Stroke Therapeutic targets Thrombosis thromboxane Thromboxane A2 vaso-occlusive crisis |
title | Thrombo-Inflammation in COVID-19 and Sickle Cell Disease: Two Faces of the Same Coin |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T15%3A37%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Thrombo-Inflammation%20in%20COVID-19%20and%20Sickle%20Cell%20Disease:%20Two%20Faces%20of%20the%20Same%20Coin&rft.jtitle=Biomedicines&rft.au=Chiang,%20Kate%20Chander&rft.date=2023-01-25&rft.volume=11&rft.issue=2&rft.spage=338&rft.pages=338-&rft.issn=2227-9059&rft.eissn=2227-9059&rft_id=info:doi/10.3390/biomedicines11020338&rft_dat=%3Cgale_doaj_%3EA742173535%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c569t-d41cf5caeebeaf34b4e0e09a8ec62a81ea3c7cec4126618fa43647683f6b412d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2779524715&rft_id=info:pmid/36830874&rft_galeid=A742173535&rfr_iscdi=true |